Vaccinex Appoints Steve Cobourn, C.P.A. as Chief Financial Officer

Rochester, NY May 12, 2014 – Vaccinex announced today that Steve Cobourn, CPA has joined the company as Chief Financial Officer and a member of the Company’s Executive Team. Steve will provide strategic and functional oversight of all Finance and Accounting activities for the Company.

Maurice Zauderer. Ph.D., Vaccinex CEO commented: “Steve joins us at an important time in the company’s development. His experience in finance and public company accounting and reporting are especially important as we plan and execute on the continued growth of our business. Steve’s extensive operational and financial experience will, I am certain, make him a highly valued colleague.”

Steve began his career as a Certified Public Accountant (CPA) at Hass & Company in Pennsylvania, where he provided audit, tax and financial advisory services to privately held companies. In 1993, Steve became Accounting Manager at the U.S. division of publicly traded Otsuka Holdings Co., Ltd., a $13 billion globally diversified company headquartered in Japan. Steve rose steadily through the ranks of the Finance organization with roles as Director of Finance & Corporate Planning, and, for the last 11 years, as Vice President of Finance, Treasurer, and Corporate Officer, responsible for all financial activities of Otsuka America Pharmaceuticals, Inc. (OAPI). During his tenure at OAPI, Steve participated in overseeing the growth of revenue from Otsuka’s U.S. operations from $10 million to $5 billion. Steve is a member of the American Institute of Public Accountants (AICPA), a Corporate Executive Board member of Accounting & Reporting, FP&A, and Shared Services Councils, and the PhRMA Accounting & Reporting Subcommittee.

About Vaccinex, Inc.

Vaccinex, Inc. based in Rochester, New York, is a privately held clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies to treat cancer and neurodegenerative diseases, including multiple sclerosis and Huntington’s disease.